CN1138565C - 聚合物键接的喜树碱衍生物 - Google Patents

聚合物键接的喜树碱衍生物 Download PDF

Info

Publication number
CN1138565C
CN1138565C CNB941907759A CN94190775A CN1138565C CN 1138565 C CN1138565 C CN 1138565C CN B941907759 A CNB941907759 A CN B941907759A CN 94190775 A CN94190775 A CN 94190775A CN 1138565 C CN1138565 C CN 1138565C
Authority
CN
China
Prior art keywords
phe
leu
gly
general formula
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB941907759A
Other languages
English (en)
Chinese (zh)
Other versions
CN1115564A (zh
Inventor
F������³ϣ
F·安格鲁希
A·苏拉托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Farmitalia Carlo Erba SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmitalia Carlo Erba SRL filed Critical Farmitalia Carlo Erba SRL
Publication of CN1115564A publication Critical patent/CN1115564A/zh
Application granted granted Critical
Publication of CN1138565C publication Critical patent/CN1138565C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
CNB941907759A 1993-10-08 1994-09-21 聚合物键接的喜树碱衍生物 Expired - Fee Related CN1138565C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939320781A GB9320781D0 (en) 1993-10-08 1993-10-08 Polymer-bound camptothecin derivatives
GB9320781.9 1993-10-08

Publications (2)

Publication Number Publication Date
CN1115564A CN1115564A (zh) 1996-01-24
CN1138565C true CN1138565C (zh) 2004-02-18

Family

ID=10743226

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB941907759A Expired - Fee Related CN1138565C (zh) 1993-10-08 1994-09-21 聚合物键接的喜树碱衍生物

Country Status (24)

Country Link
US (1) US5773522A (cg-RX-API-DMAC7.html)
EP (1) EP0673258B1 (cg-RX-API-DMAC7.html)
JP (1) JPH08504217A (cg-RX-API-DMAC7.html)
KR (1) KR100359005B1 (cg-RX-API-DMAC7.html)
CN (1) CN1138565C (cg-RX-API-DMAC7.html)
AT (1) ATE239507T1 (cg-RX-API-DMAC7.html)
AU (1) AU679788B2 (cg-RX-API-DMAC7.html)
CA (1) CA2150132A1 (cg-RX-API-DMAC7.html)
DE (1) DE69432627T2 (cg-RX-API-DMAC7.html)
DK (1) DK0673258T3 (cg-RX-API-DMAC7.html)
ES (1) ES2198421T3 (cg-RX-API-DMAC7.html)
FI (1) FI952746A7 (cg-RX-API-DMAC7.html)
GB (1) GB9320781D0 (cg-RX-API-DMAC7.html)
HU (1) HU215588B (cg-RX-API-DMAC7.html)
IL (1) IL111173A (cg-RX-API-DMAC7.html)
MY (1) MY116624A (cg-RX-API-DMAC7.html)
NZ (1) NZ273952A (cg-RX-API-DMAC7.html)
PL (1) PL178132B1 (cg-RX-API-DMAC7.html)
PT (1) PT673258E (cg-RX-API-DMAC7.html)
RU (1) RU2149646C1 (cg-RX-API-DMAC7.html)
TW (1) TW316905B (cg-RX-API-DMAC7.html)
UA (1) UA42706C2 (cg-RX-API-DMAC7.html)
WO (1) WO1995010304A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA947823B (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5646159A (en) * 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
DE19512484A1 (de) 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
CA2192725C (en) * 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
WO1998014459A1 (de) * 1996-09-30 1998-04-09 Bayer Aktiengesellschaft Glycokonjugate von modifizierten camptothecin-derivaten (20-o-verknüpfung)
DE19640969A1 (de) * 1996-10-04 1998-04-16 Bayer Ag 20-0-verknüpfte Glycokonjugate von Camptothecin
ID23424A (id) * 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
GB9721069D0 (en) * 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
GB9721070D0 (en) * 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Bioactive derivatives of camptothecin
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
GB9915180D0 (en) * 1999-06-29 1999-09-01 Pharmacia & Upjohn Spa Antitumour compound
JP4776843B2 (ja) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
US20030054977A1 (en) * 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
AU1820400A (en) * 1999-11-17 2001-05-30 School Of Pharmacy, University Of London, The Conjugates of hpma copolymer and ellipticin
US20020077290A1 (en) * 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
GB0008928D0 (en) * 2000-04-11 2000-05-31 Pharmacia & Upjohn Spa A method of administering an antitumour compound
US6350756B1 (en) 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
US6855720B2 (en) 2001-03-01 2005-02-15 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6403604B1 (en) 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
WO2003033525A1 (en) * 2001-10-12 2003-04-24 Debio Recherche Pharmacuetique S.A. Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
US6933302B2 (en) 2002-06-03 2005-08-23 California Pacific Medical Center Nitrogen-based homo-camptothecin derivatives
ITPD20050242A1 (it) * 2005-08-03 2007-02-04 Fidia Farmaceutici Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico
US7875602B2 (en) 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
CN101265331B (zh) * 2007-03-12 2010-10-13 中国科学院化学研究所 Peg改性phpma材料及其制备方法
WO2011150022A2 (en) 2010-05-25 2011-12-01 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
EP3574922B1 (en) * 2013-04-10 2021-09-15 Syndevrx, Inc. Modified or polymer-conjugated fumagillol metap2 inhibitors for use in improving or restoring insulin sensitivity
JP6529130B2 (ja) * 2013-08-26 2019-06-12 国立研究開発法人科学技術振興機構 接着剤
KR102849342B1 (ko) 2015-12-10 2025-08-21 신데브알엑스, 인크. 푸마길롤 유도체 및 그의 다형체
AU2017206718B2 (en) 2016-01-11 2021-09-30 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
US11612577B2 (en) 2018-10-26 2023-03-28 Syndevrx, Inc. Biomarkers of METAP2 inhibitors and applications thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
GB9309663D0 (en) * 1993-05-11 1993-06-23 Erba Carlo Spa Biologically active compounds

Also Published As

Publication number Publication date
AU679788B2 (en) 1997-07-10
EP0673258B1 (en) 2003-05-07
NZ273952A (en) 1996-10-28
FI952746A0 (fi) 1995-06-05
ATE239507T1 (de) 2003-05-15
CA2150132A1 (en) 1995-04-20
MY116624A (en) 2004-03-31
IL111173A (en) 1998-10-30
PL309328A1 (en) 1995-10-02
KR100359005B1 (ko) 2003-04-26
ES2198421T3 (es) 2004-02-01
UA42706C2 (uk) 2001-11-15
GB9320781D0 (en) 1993-12-01
TW316905B (cg-RX-API-DMAC7.html) 1997-10-01
DK0673258T3 (da) 2003-08-25
CN1115564A (zh) 1996-01-24
PT673258E (pt) 2003-09-30
WO1995010304A1 (en) 1995-04-20
ZA947823B (en) 1995-07-03
DE69432627T2 (de) 2004-03-25
HU9502084D0 (en) 1995-09-28
IL111173A0 (en) 1994-12-29
HU215588B (hu) 1999-01-28
US5773522A (en) 1998-06-30
FI952746A7 (fi) 1995-06-05
AU7783694A (en) 1995-05-04
HUT71678A (en) 1996-01-29
JPH08504217A (ja) 1996-05-07
DE69432627D1 (en) 2003-06-12
RU2149646C1 (ru) 2000-05-27
RU95112841A (ru) 1997-06-27
EP0673258A1 (en) 1995-09-27
PL178132B1 (pl) 2000-03-31

Similar Documents

Publication Publication Date Title
EP0673258B1 (en) Polymer-bound camptothecin derivatives
CN1309763C (zh) 喜树碱的高分子衍生物
CN1041281C (zh) 聚合物键合的紫杉醇衍生物
JP5008783B2 (ja) 高分子量のポリマーを基剤とするプロドラッグ
US8808749B2 (en) Polymer conjugate of bioactive substance having hydroxy group
EP2042195A1 (en) Polymer conjugate of combretastatin
EP2258397A1 (en) Polymer conjugate of physiologically active substance
CN1761485B (zh) 含略微水溶性抗癌剂和新型嵌段共聚物的胶束制剂
WO2001019407A2 (en) Taxane prodrugs
Deshmukh et al. A series of α-amino acid ester prodrugs of camptothecin: in vitro hydrolysis and A549 human lung carcinoma cell cytotoxicity
CN106750272A (zh) 一种水溶性蛇葡萄素聚合物
CN1449412A (zh) Dds化合物及其制备方法
CN100406010C (zh) 抗癌剂及其制备方法
CN1676525A (zh) 亲水性聚合物-雷公藤提取物的结合物及其药物组合物
JP2004504358A (ja) 抗腫瘍薬のポリマー複合体
CN1895676A (zh) 聚乙二醇为载体的紫杉醇或多烯紫杉醇的前药
CN110152013B (zh) 一种果胶-阿霉素轭合物及其制备方法和用途
CN119039483A (zh) 一种靶向DC细胞的mRNA递送系统及其制备方法
CN113786492B (zh) 一种可用于光动力治疗的聚合物载体及其制备方法和用途
CN110418653B (zh) 一种果胶-阿霉素轭合物及其制备方法和用途
US20120094892A1 (en) Prodrugs
CN1623993A (zh) 新型的斑蝥胺和去甲斑蝥胺衍生物及其在医药中的应用
HK1032005A1 (en) Polymeric derivatives of camptothecins
CN102188716A (zh) 以氨基酸或寡肽为连接子的大分子-长春碱偶合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CI01 Publication of corrected invention patent application

Correction item: International date of application, international application number, international date of entry

Correct: 1994.09.21 PCT/EP1994/03154 1995.06.08

Number: 7

Page: 370

Volume: 20

CI03 Correction of invention patent

Correction item: International date of application, international application number, international date of entry

Correct: 1994.09.21 PCT/EP1994/03154 1995.06.08

Number: 7

Page: The title page

Volume: 20

COR Change of bibliographic data

Free format text: CORRECT: INTERNATIONAL APPLICATION DATE INTERNATIONAL APPLICATION NO. ENTERING DATE OF INTERNATIONAL PUBLICATION TO: 1994.9.21 PCT/EP1994/03154 1995.6.8

ERR Gazette correction

Free format text: CORRECT: INTERNATIONAL APPLICATION DATE INTERNATIONAL APPLICATION NO. ENTERING DATE OF INTERNATIONAL PUBLICATION; 1994.9.21 PCT/EP1994/03154 1995.6.8

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee